The detail
Transvaginal ultrasound first (endometrial thickness >4 mm prompts biopsy). Endometrial biopsy gold standard. Hysteroscopy if biopsy non-diagnostic. Most causes benign (atrophy, polyps, hormonal therapy effects), but cancer rule-out essential. Don't delay — even one episode warrants evaluation.
Historical context
The urgency around postmenopausal bleeding is one of the clearest rules in women's health, precisely because bleeding after menopause is the most common presenting sign of endometrial cancer — even though most causes turn out to be benign.
Research landscape
Any bleeding after 12 months without a period is treated as needing prompt evaluation, not watchful waiting, because excluding endometrial cancer is time-sensitive. Standard assessment includes a transvaginal ultrasound to measure the endometrial lining and, depending on findings and risk, an endometrial biopsy or hysteroscopy. Most cases are ultimately explained by benign causes (atrophy, polyps, or hormone therapy effects), but the work-up is done first to rule out the serious ones. The emphasis is on weeks, not months — this is not a symptom to monitor at home.
What providers actually do
Clinicians treat postmenopausal bleeding as a "come in and get assessed" symptom regardless of how light it is, and they do not attribute it to hormones or atrophy until cancer has been excluded through appropriate testing.
Subtle red flags specific to this question
- ANY bleeding or spotting after 12 months without a period — arrange prompt evaluation; do not wait.
- Bleeding with pelvic pain, weight loss, or a foul-smelling discharge — seek care sooner.
- Being reassured it is "just atrophy" without any imaging or biopsy — ask for the work-up.
- Recurrent bleeding on hormone therapy beyond the expected settling-in period — needs assessment.
Sources
Was this helpful?